# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

- acknowledge government support

## BACKGROUND OF THE INVENTION

- discuss origins of primordial germ cells
- summarize limitations of prior methods

## BRIEF SUMMARY OF THE INVENTION

- outline method of forming primordial germ cells
- describe method of isolating primordial germ cells
- summarize applications of invention

## DETAILED DESCRIPTION OF THE INVENTION

- outline compositions and methods

### Definitions

- define scope of invention
- clarify section headings
- incorporate references by reference
- define singular and plural articles
- define open-ended terms
- define "about"
- define "nucleic acid"
- define "polynucleotide"
- describe nucleic acid structure
- define "reactive moiety"
- describe nucleic acid analogs
- define "labeled nucleic acid"
- define "label" or "detectable moiety"
- describe nonspecific sequences
- define "complementary" and "complementarity"
- describe stringent hybridization conditions
- define "gene" and "expression"
- define transcription start site
- define promoter
- define enhancer
- define silencer
- define amino acid
- define polypeptide, peptide, and protein
- define conservatively modified variants
- define percentage of sequence identity
- define identical or percent identity
- define amino acid or nucleotide base position
- define numbered with reference to
- define specific proteins (e.g., TGFβ, BMP4, CXCR4, PDGFRα, SCF, EGF)
- define PDGFRα
- define CXCR4
- define BMP
- define EGF
- define Wnt protein
- define detectable agent or detectable moiety
- define recombinant
- define isolated nucleic acid or protein
- define cell
- define primordial germ cell
- define epiblast
- define posterior epiblast
- define stem cell
- define pluripotent stem cells
- define cell culture media
- specify culture media components
- specify serum concentrations
- specify supplements and antibiotics
- define cell culture container
- specify types of cell culture containers
- define surface coating materials
- describe cell culture conditions
- define vector and expression vector
- explain transfection and transduction
- define contacting
- describe inhibition and repression
- define inhibitor and antagonist
- define agonist and activator
- explain control samples and values
- provide examples of commercially available gels
- describe MATRIGEL composition
- define patient
- define disease or condition
- define treatment
- explain therapeutic benefit
- explain prophylactic benefit
- define dose and dosage form
- define effective amount
- explain reduction of symptoms
- define activity decreasing amount
- define function disrupting amount
- explain administering
- explain co-administering
- describe formulations for oral administration
- describe formulations for parenteral administration
- describe formulations for rectal administration
- explain pharmaceutical preparation
- define pharmaceutically acceptable excipient
- define pharmaceutically acceptable salt

### Methods

- provide simplified 2D in vitro platform
- introduce method of forming PGC in vitro
- describe contacting pluripotent stem cell population with WNT agonist and TGFβ agonist
- describe contacting posterior epiblast cell population with WNT inhibitor
- introduce method of isolating PGC
- describe contacting pluripotent stem cell population with WNT agonist and TGFβ agonist
- describe contacting posterior epiblast cell population with WNT inhibitor
- describe separating CXCR4+/PDGFRα-/GARP cell from cell population
- define term "separating"
- define "pluripotent stem cell population"
- define "posterior epiblast cell population"
- describe WNT inhibitor
- describe WNT agonist and TGFβ agonist
- list TGFβ agonists
- define Activin-A protein
- specify Activin-A concentrations
- list WNT inhibitors
- define CHIR99021
- specify CHIR99021 concentrations
- define Y-27632
- specify Y-27632 concentrations
- list TGFβ agonist embodiments
- list WNT agonist embodiments
- list Y-27632 embodiments
- specify Activin-A concentrations range
- specify CHIR99021 concentrations range
- specify Y-27632 concentrations range
- list specific Activin-A concentrations
- list specific CHIR99021 concentrations
- list specific Y-27632 concentrations
- define methods
- specify contacting duration
- specify PGC formation duration
- describe expanding cell populations
- specify contacting with BMP, SCF, EGF
- define BMP-4
- specify BMP-4 concentration
- specify BMP-4 concentration range
- define XAV939
- specify XAV939 concentration
- specify XAV939 concentration range
- specify XAV939 concentration range
- specify XAV939 concentration range
- specify XAV939 concentration range
- specify XAV939 concentration range
- specify XAV939 concentration range
- specify XAV939 concentration range
- specify XAV939 concentration range
- define XAV939 concentration
- define SCF protein
- specify SCF concentration
- define EGF protein
- specify EGF concentration
- describe contacting methods
- describe cell culture conditions
- specify pluripotency marker genes
- specify cell population types

### Cell Compositions

- define cell culture compositions
- specify cell types and medium components

### METHODS OF USE

- outline methods of using PGCs

### EXAMPLES

- introduce PGCs
- describe current limitations of PGC generation
- introduce simplified monolayer method
- describe WNT activation and BMP activation
- describe pluripotency factors during transition
- describe purification of PGCs by surface markers
- introduce background on PGC origins
- describe differences between human and mouse PGC development
- describe previous methods to generate PGCs
- describe limitations of previous methods
- introduce goal of developing simplified 2D platform
- describe initial observations on PGC generation
- describe optimization of culture conditions
- describe single-cell RNA-sequencing analysis
- describe temporally dynamic WNT signaling
- describe optimization of BMP, SCF, LIF, and EGF activation
- describe development of monolayer, serum-free protocol
- describe surface-marker profile of hPSC-derived PGCs
- describe consistency of PGC generation across hESC and hiPSC lines
- introduce PGC purification strategy
- demonstrate PGC marker expression
- perform single-cell RNA sequencing
- analyze scRNAseq data for PGC specification
- identify PGC and non-PGC populations
- validate PGC marker expression
- discuss PGC development and signaling pathways
- discuss relationship between PGC and PS lineages
- discuss temporal and combinatorial logic of WNT signaling
- discuss continued pluripotency factor expression
- discuss limitations of PGC formation efficiency
- describe hPSC culture and maintenance
- describe PGC differentiation protocol
- describe immunostaining and flow cytometry procedures
- describe high-throughput cell-surface marker screening
- describe RNA extraction and reverse transcription
- outline quantitative PCR (qPCR) procedure
- detail single cell RNA-sequencing protocol
- explain single cell RNA-seq computational analysis
- present surface marker screen of PGCs, non-PGCs and undifferentiated hPSCs
- list references
- introduce primordial germ cells (PGCs) and their specification
- discuss human embryonic stem cells and their differentiation
- describe germ cell fate specification in mice
- outline human germ cell development and specification
- discuss pluripotent stem cell lines and their differentiation
- summarize germ cell lineage specification from pluripotent stem cells

## P EMBODIMENTS

- define PGC formation method
- define PGC isolation method
- describe variations of PGC formation and isolation methods

### EMBODIMENTS

- define PGC formation method
- define PGC isolation method
- describe variations of PGC formation and isolation methods
- describe in vitro cell cultures and compositions
- describe method of treating infertility

